- page

Scroll to explore

Scroll back top

Domain presents a novel approach to study RTK mutations and the effects of inhibitors at the AACR 20...

Domain presents target identification strategy to identify novel immune checkpoint from GPCR-ome at ...

Domain presents the best-in-class potential of its EP4 antagonist drug candidate at the AACR 2020

Domain Therapeutics contributes to the launch of Find Therapeutics

DOMAIN at the BIO Digital conference 2020

Domain Therapeutics receives development milestone payment from Merck KGaA, Darmstadt, Germany, fo...

Domain at the BioTrinity 2020 digital conference

Domain Therapeutics acquires Prestwick Chemical and Neurofit to bolster next stage of growth

4 February 2020

Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking

13 January 2020

Domain Therapeutics secures €6 million ($6.7M) debt financing